List of Blueprint Medicines patents

Patents where

Current Assignee

Name

Blueprint Medicines

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10030005 Inhibitors of RET	Patent 10030005 was granted and assigned to Blueprint Medicines on July, 2018 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	10030005	July 24, 2018
‌ US Patent 10202365 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors	Patent 10202365 was granted and assigned to Blueprint Medicines on February, 2019 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	10202365	February 12, 2019
‌ US Patent 11273160 RET inhibitor for use in treating cancer having a RET alteration	Patent 11273160 was granted and assigned to Blueprint Medicines on March, 2022 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	11273160	March 15, 2022
‌ US Patent 10000490 Inhibitors of the fibroblast growth factor receptor	Patent 10000490 was granted and assigned to Blueprint Medicines on June, 2018 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	10000490	June 19, 2018
‌ US Patent 10017512 Compounds and compositions useful for treating disorders related to NTRK	Patent 10017512 was granted and assigned to Blueprint Medicines on July, 2018 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	10017512	July 10, 2018
‌ US Patent 10227329 Compounds useful for treating disorders related to RET	Patent 10227329 was granted and assigned to Blueprint Medicines on March, 2019 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	10227329	March 12, 2019
‌ US Patent 10233186 Inhibitors of activin receptor-like kinase	Patent 10233186 was granted and assigned to Blueprint Medicines on March, 2019 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	10233186	March 19, 2019
‌ US Patent 10035789 Compounds useful for treating disorders related to RET	Patent 10035789 was granted and assigned to Blueprint Medicines on July, 2018 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	10035789	July 31, 2018
‌ US Patent 10000496 Compositions useful for treating disorders related to kit and PDGFR	Patent 10000496 was granted and assigned to Blueprint Medicines on June, 2018 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	10000496	June 19, 2018
‌ US Patent 10584114 Inhibitors of RET	Patent 10584114 was granted and assigned to Blueprint Medicines on March, 2020 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	10584114	March 10, 2020
‌ US Patent 11279688 Inhibitors of RET	Patent 11279688 was granted and assigned to Blueprint Medicines on March, 2022 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	11279688	March 22, 2022
‌ US Patent 10196436 Inhibitors of the fibroblast growth factor receptor	Patent 10196436 was granted and assigned to Blueprint Medicines on February, 2019 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	10196436	February 5, 2019
‌ US Patent 10183928 Inhibitors of RET	Patent 10183928 was granted and assigned to Blueprint Medicines on January, 2019 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	10183928	January 22, 2019
‌ US Patent 10221154 Inhibitors of the fibroblast growth factor receptor	Patent 10221154 was granted and assigned to Blueprint Medicines on March, 2019 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	10221154	March 5, 2019
‌ US Patent 10378063 RAF1 fusions	Patent 10378063 was granted and assigned to Blueprint Medicines on August, 2019 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	10378063	August 13, 2019
‌ US Patent 11634422 Inhibitors of activin receptor-like kinase	Patent 11634422 was granted and assigned to Blueprint Medicines on April, 2023 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	11634422	April 25, 2023
‌ US Patent 9340514 Inhibitors of the fibroblast growth factor receptor	Patent 9340514 was granted and assigned to Blueprint Medicines on May, 2016 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	9340514	May 17, 2016
‌ US Patent 11534441 MAP4K1 inhibitors	Patent 11534441 was granted and assigned to Blueprint Medicines on December, 2022 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	11534441	December 27, 2022
‌ US Patent 9499522 Compositions useful for treating disorders related to kit	Patent 9499522 was granted and assigned to Blueprint Medicines on November, 2016 by the United States Patent and Trademark Office.		Blueprint Medicines	United States Patent and Trademark Office	9499522	November 22, 2016
‌ US Patent 11236086 Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase	Patent 11236086 was granted and assigned to Blueprint Medicines on February, 2022 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	11236086	February 1, 2022
‌ US Patent 9695165 Inhibitors of the fibroblast growth factor receptor	Patent 9695165 was granted and assigned to Blueprint Medicines on July, 2017 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	9695165	July 4, 2017
‌ US Patent 9334263 Compositions useful for treating disorders related to kit	Patent 9334263 was granted and assigned to Blueprint Medicines on May, 2016 by the United States Patent and Trademark Office.		Blueprint Medicines	United States Patent and Trademark Office	9334263	May 10, 2016
‌ US Patent 9994575 Compositions useful for treating disorders related to kit	Patent 9994575 was granted and assigned to Blueprint Medicines on June, 2018 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	9994575	June 12, 2018
‌ US Patent 9944651 Compositions useful for treating disorders related to kit	Patent 9944651 was granted and assigned to Blueprint Medicines on April, 2018 by the United States Patent and Trademark Office.	Blueprint Medicines	Blueprint Medicines	United States Patent and Trademark Office	9944651	April 17, 2018
‌ US Patent 9126951 Inhibitors of the fibroblast growth factor receptor	Patent 9126951 was granted and assigned to Blueprint Medicines on September, 2015 by the United States Patent and Trademark Office.		Blueprint Medicines	United States Patent and Trademark Office	9126951	September 8, 2015

Results per page:

51 results

0 selected

51 results

0 selected